After patient deaths, failed partnerships and a stock scandal, Hanmi finally gives up on controversial olmutinib. What did we learn?
The olmutinib development program is finally dead.
South Korea’s Hanmi has determined that the drug — once partnered with Boehringer Ingelheim and Zai Lab — is no longer commercially viable. The drug was seen as more or less equivalent to AstraZeneca’s Tagrisso, according to Hanmi. So they’ve opted to punt the late-stage trial and shelve it once and for all.
“We will thoroughly review the plan, putting patients’ safety first and foremost,” Korea’s health ministry said in a statement, according to Korea Biomedical Review. “We will also do our utmost to make sure that patients who are taking the medication will not face any difficulty in their treatment.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
